期刊文献+

匹伐他汀的药理作用及临床应用 被引量:20

Pharmacological effects and clinical application of pitavastatin
原文传递
导出
摘要 匹伐他汀(pitavastatin)是新一代HMG-CoA还原酶抑制剂,能显著降低低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)及升高高密度脂蛋白胆固醇(HDL-C),药动学性质优良,具有肝细胞选择性,且毒性低,安全性好,具有抗动脉粥样硬化、促血管生成和抗炎作用。现对其药理作用、临床研究及不良反应等做一综述。 Pitavastatin is a novel,fully synthetic HMG-CoA reductase inhibitor,which can significantly reduce low-density lipoprotein cholesterol(LDL-C),triglycerides(TG),and also increase high-density lipoprotein cholesterol(HDL-C).The drug is well tolerated and safe.It not only has potent cholesterol-lowering effects,but also has anti-atherosclerotic,angiogenesis-promoting and anti-inflammatory effects by selectively acting on liver cells.In this paper,we reviewed pharmacology,pharmacotherapy and adverse reactions of pitavastatin.
出处 《中国新药杂志》 CAS CSCD 北大核心 2009年第5期383-386,402,共5页 Chinese Journal of New Drugs
关键词 匹伐他汀 HMG-COA还原酶抑制剂 降血脂药 pitavastatiu HMG-CoA reductase inhibitor cholesterol-lowering drug
  • 相关文献

参考文献28

  • 1董亚琳,董卫华.他汀类药物的研究进展[J].中国新药杂志,2003,12(3):175-178. 被引量:62
  • 2国大亮,张广雪,孙海英.超级他汀家族新成员-匹伐他汀(Pitavastatin calcium)[J].齐鲁药事,2004,23(1):61-62. 被引量:9
  • 3BOLEGO C, POLI A, CIGNARELLA A, et al. Novel statins: Pharmacological and clinical results [ J ]. Cardiovasc Drugs Ther, 2002,16(3) : 251 -257.
  • 4SUZUKI M, IWASAKI H, FUJIKAWA Y, et al. Synthesis and biological evalutions of quinoline-based HMG-CoA reductase inhibitors[ J]. Bioarg Med Chem,2001,9 (10) : 2727 -2743.
  • 5何笑荣,邹定,姜文清,马捷,李金娥.降血脂新药匹伐他汀[J].中国新药杂志,2005,14(4):483-487. 被引量:31
  • 6SATA M, NISHIMATSU H, SLZUKI E, et al. Endothelial nitric oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia [J]. FASEB J, 2001, 15(13):2530-2532.
  • 7POURATI I, KIMMELSTIEL C, RAND W, et al. Statin use is associated with enhanced collateralization of severely diseased coronary arteries[ J ]. Am Heart J, 2004, 148 (5) : 21 - 23.
  • 8TOKORO T, WANG J, KITAJIMA I, et al. The novel HMG- CoA reductase inhibitor, pitavastatin, induces a protective action in vascular endothelial cells through the production of nitric oxide (NO)[J]. Yakugaku Zasshi, 2004,124(3) :121 -126.
  • 9张月兰,田文,张子新,曾定尹,齐国先.匹伐他汀对Klotho基因敲除杂合子小鼠血管新生的促进作用[J].中国应用生理学杂志,2006,22(2):163-167. 被引量:3
  • 10张月兰,程颖,李轶男,曾定尹,齐国先.不同剂量匹伐他汀对小鼠缺血肢血流恢复的影响[J].中国医科大学学报,2006,35(3):251-252. 被引量:2

二级参考文献54

  • 1HAYASHI T, AROCKIA J, FUKATSU A, et al. A new HMGCoA reductase inhibitor, pitavastatin remarkably retards the progression of high cholesterol induced atherosclerosis in rabbits[ J ]. Atherosclerosis, 2004, 176(2) :255 - 263.
  • 2SHITARA Y, SUGIYAMA Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions[J]. Pharmacol Ther, 2006, 112(1): 71-105.
  • 3SAITO Y, YAMADA N, TERAMOTO T, et al. Clinical efficacy of pitavastatin, a new of 3-hydroxy-3-methylglutaryl coenzyme reductase inhibitor, in patients with hyperlipidemia[ J]. Arzneimittelforsch, 2002, 52(4) :251 - 255.
  • 4SAITO Y, YAMADA N, TERAMOTO T, et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin verus pravastatin in patients with primary hypercholesterolemia [J]. Atheroslerosis, 2002, 162(2) :373 -379.
  • 5Kajinami K, Koizumi J, Ueda K, et al. Effects of NK- 104, a new hydroxymethyglutaryl-coenzyme reductase inhibitor,on low-density lipoprotein cholesterol in heterozygous familial hyperc holesterolemia. Hokuriku NK-104 study group[J].Am J Cardiol,2000,85(2) : 178 - 183.
  • 6Sone H, Takahashi A, Shimano H, et al. HMG-OoA reductase inhibitor decreases small dense low-density lipoprotein and remnanlike particle cholesterol in patients with type-2 diabetes[J ].Life Sci, 2002,71 (20) : 2403 - 2412.
  • 7Akiba T, Shibuta T, Amano Y, et al. Six-month repeated oral toxicity study of NK-104 in rats[J]. J Toxicol Sci, 1998,23(Suppl 5) :S713 - S720.
  • 8Akiba T, Shibuta T, Amano Y, et al. 28-day repeated oral toxicity study of a hypolipidemic agent, NK-104 in rats[J]. J Toxicol Sci,1998,23(Suppl 5) :S701-S711.
  • 9Suzuki M, lwasaki H, Fuj;kawa Y, et al. Synthesis and biological evalutions of quinoline-based HMG-CoA reductase inhibitors[J].Bioorg Med Chem ,2001,9(10) :2727-2743.
  • 10Morikawa S, Umetani M, Nakagawa S, et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells[J] .J Atheroscler Thromb ,2000,7(3):138-144.

共引文献107

同被引文献139

引证文献20

二级引证文献78

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部